Descemet Endothelial Thickness Comparison Trial II

Phase 3 Recruiting 60 enrolled Stanford University Case Western Reserve University · collab Dartmouth-Hitchcock Medical Center · collab Devers Eye Institute · collab Oregon Health and Science University · collab University of California, Davis · collab University of California, San Francisco · collab University of Miami · collab University of Pennsylvania · collab Wills Eye Hospital · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.

Timeline

Start: 2023-01-23
Primary completion: 2027-11-30
Completion: 2028-11-30

Publications

Lin CC, Chamberlain W, Benetz BA, Gensheimer W, Li JY, Jeng BH, Clover J, Varnado N, Abdelrahman S, Srinivasan A, Syed ZA, Koo EH, Arnold BF, Lietman TM, Lass J, Rose-Nussbaumer J. Descemet Endothelial Thickness Comparison Trial II (DETECT II): multicentre, outcome assessor-masked, placebo-controlled trial comparing Descemet membrane endothelial keratoplasty (DMEK) to Descemet stripping only (DSO) with adjunctive ripasudil for Fuchs dystrophy. BMJ Open Ophthalmol. 2024 Oct 1;9(1):e001725. doi: 10.1136/bmjophth-2024-001725.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ripasudil	Small molecule	0.4 %	Topical

Descemet Endothelial Thickness Comparison Trial II

Summary

Timeline

Publications

Drugs

Indications